ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision (NYSE Amex:ISV) today announced that it has signed an exclusive international licensing and distribution agreement for AzaSite® (azithromycin ophthalmic solution) 1% with Nitten Pharmaceutical Co., Ltd., one of the top ten Japanese ophthalmic pharmaceutical companies. AzaSite contains a broad-spectrum antibiotic formulated with InSite Vision’s patented DuraSite® drug delivery vehicle to enhance the retention time of the antibiotic on the surface of the eye. AzaSite offers the benefit of a less frequent and more convenient dosing regimen in a safe and effective therapy for the treatment of bacterial eye infections.
